Acute coronary syndrome drug market to reach around $2.8 billion in 2020

The uptake of oral agents with novel modes of action such as AstraZeneca’s ADP receptor antagonist Brilinta/Brilique (ticagrelor will drive sales in the 12-month post-hospital acute coronary syndrome (ACS) drug market to reach about $2.8 billion in 2020 in the USA, France, Germany, Italy, Spain, the UK and Japan, according to a new report from advisory firm Decision Resources.

The findings from DR’s Pharmacor topic titled Acute Coronary Syndrome reveal that the 12-month post-hospital ACS market will initially contract from $1.5 billion in 2010 to just under $1.4 billion in 2013, due mainly to the generic erosion in the USA of clopidogrel (Bristol-Myers Squibb/Sanofi’s Plavix/Iscover). Thereafter, the market will double, owing largely to the uptake of Brilinta/Brilique as well the CETP inhibitors anacetrapib (Merck & Co) and dalcetrapib (from Roche/Japan Tobacco).

“We expect dalcetrapib to be the first CETP inhibitor to launch for ACS in 2014, followed by anacetrapib in 2018,” said Decision Resources analyst Conor Walsh, adding: “We anticipate both agents will demonstrate significant reductions in cardiovascular events in their Phase III trials without exhibiting ‘off-target’ toxicities like their predecessor, Pfizer’s torcetrapib. Consequently, we forecast that the CETP inhibitor drug class will comprise approximately 20 percent of total sales in this market in 2020.”